CD40LG and cancer: Since CD40/CD40L are essential components in both innate and acquired immunity, monoclonal antibodies targeting CD40/CD40L, either antagonistic or agonistic, have attracted widespread attention in the field of autoimmune diseases and cancers, respectively (Karnell et al., 2019; Bullock 2022).